Vorasidenib
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications
Reproductive health considerations for IDH-mutant glioma patients considering IDH inhibitor therapy: A retrospective cohort study.
Journal: Neuro-oncology practice
Published: December 29, 2025
"Vorasidenib and Low-Grade Glioma: INDIGO Incremental Insights".
Journal: Neuro-oncology
Published: December 08, 2025
Integration and Intersection of Cancer Metabolism with Epigenetic Pathways in Gliomas.
Journal: Annual review of pathology
Published: November 18, 2025
Comparing Isocitrate Dehydrogenase Inhibitors with Procarbazine, Lomustine, and Vincristine Chemotherapy for Oligodendrogliomas.
Journal: Cancers
Published: November 13, 2025
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, panitumumab plus sotorasib for colorectal cancer, and vorasidenib for glioma.
Journal: International journal of clinical oncology
Published: October 25, 2025
Understanding and imaging PHGDH-driven intrinsic resistance to mutant IDH inhibition in gliomas.
Journal: bioRxiv : the preprint server for biology
Published: September 15, 2025
The role of amino acid PET in the era of checkpoint inhibitors and targeted therapy for brain tumor treatment.
Journal: Current opinion in neurology
Published: August 13, 2025
Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications.
Journal: Current therapeutic research, clinical and experimental
Published: August 07, 2025
New biochemical approaches for the treatment of glioblastoma.
Journal: The Journal of biological chemistry
Published: August 02, 2025
Last Updated: 02/24/2026